Prothena (PRTA)
(Delayed Data from NSDQ)
$20.56 USD
0.00 (0.00%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $20.67 +0.11 (0.54%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 61 - 80 ( 329 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Novel Compounds to Treat ATTR Amyloidosis Appear on Track to Generate Peak Annual Revenues of $50B-Plus
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Bird''s Eye View of Disease-Modifying Targets of Parkinson''s Disease-AD/PD 2022 Live from Barcelona
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Killing Two Birds with One Stone is Prothena''s Mantra for AD Vaccine
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Do You Know About the Current State-of-the-Art AD/PD Biomarkers?
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Next-Generation Anti-Abeta Antibody PRX012 Remains the Focus for 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Disentangling PRX012 from Aducanumab Creates Opportunity
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Prothena''s AD Portfolio have Considerable Upside¯Our Thoughts; Reit Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Dual Abeta-Tau Vaccine - Killing Two Birds With One Stone
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Prothena Prepping for an Acquisition: Our Thoughts; Reit Buy and Raising to PT $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A